FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Aarhus University Hospital
Århus, DinamarcaPublicaciones en colaboración con investigadores/as de Aarhus University Hospital (27)
2024
-
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
Radiotherapy and Oncology
-
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83
2023
-
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis
Cancer Treatment Reviews, Vol. 119
-
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis
Radiotherapy and Oncology, Vol. 186
2022
-
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
Osteoporosis International, Vol. 33, Núm. 12, pp. 2527-2536
2020
-
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649
2019
-
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911
-
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies
Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200
2018
-
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657
-
Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371
-
Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database
Critical Care, Vol. 22, Núm. 1
-
Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies
Bone, Vol. 116, pp. 58-66
2017
-
Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial
Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051
-
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594
2016
-
Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks
Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878
-
Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines
Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84
-
Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
Calcified Tissue International, Vol. 99, Núm. 3, pp. 259-271
-
Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)
Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189
2013
2012
-
Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-Year results from the EFOS study
Journal of Rheumatology, Vol. 39, Núm. 3, pp. 600-609